阿帕替尼联合紫杉醇二线治疗在Her-2阴性晚期胃癌患者中的应用效果

Abstract
Figure/Table
References (16)
Related Citation (15)

Download: PDF (488 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the effect of Apatinib combined with Paclitaxel in the second-line treatment of Her-2 negative advanced gastric cancer patients. Methods A total of 96 patients with Her-2 negative advanced gastric cancer who were treated at Shangrao People′s Hospital in Jiangxi from January 2018 to January 2021 were selected as the subjects of this study, and they were divided into the control group and the study group by simple randomization method, with 48 cases in each group. Patients in the control group were treated with Paclitaxel alone, and patients in the study group were treated with Apatinib combined with Paclitaxel as second-line treatment. The clinical efficacy,adverse reactions and progression-free survival time of the two groups of patients were compared. Results The total effective rate, disease control rate in the study group after treatment were higher than those in the control group, and progression-free survival time of the patients in the study group after treatment was longer than that in the control group,the differences were statistically significant (P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P>0.05). Conclusion The second-line treatment of Apatinib combined with Paclitaxel can significantly improve the clinical efficacy of HER-2 negative patients with advanced gastric cancer, effectively prolong the progression free survival time, and is conducive to the control of the disease. At the same time, there is a certain degree of safety and no serious adverse situation. It is worthy of widespread clinical promotion.

Key words： Advanced gastric cancer Paclitaxel Apatinib Advanced chemotherapy

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HAN Yongqing
	FU Feng
	HUANG Kairong

Cite this article:

HAN Yongqing,FU Feng,HUANG Kairong. Efficacy and safety of second-line treatment with Apatinib and Paclitaxel for HER-2 negative advanced gastric cancer[J]. 中国当代医药, 2022, 29(8): 83-85转90.

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2022/V29/I8/83

[11]	赵妍，张明晖，孙雅丽，等.紫杉醇联合阿帕替尼对比单药紫杉醇二线治疗胃癌的真实世界前瞻性研究[J].中国肿瘤临床，2020，47（15）：34-37.
[12]	许晓东，徐志英，谢君.紫杉醇脂质体治疗进展期胃癌的疗效及安全性研究[J].中国现代医学杂志，2020，30（5）：13-116.
[13]	郭健，郑龙志，林伟.紫杉醇腹腔灌注联合替吉奥治疗晚期胃癌腹膜转移的研究进展[J].中国医药科学，2020，10（16）：40-44.
[1]	毕延智，李小倩，肖敏，等.小剂量阿帕替尼联合紫杉醇脂质体与雷替曲塞二线治疗晚期胃癌的疗效及安全性[J].中国肿瘤临床与康复，2019,26（1）：36-39.
[2]	齐倩，王春梅，杨娟，等.阿帕替尼治疗一线及二线化疗失败晚期非小细胞肺癌患者临床疗效研究[J].临床军医志，2019，47（1）：92-94.
[3]	李静，贾永旭，秦艳茹.阿帕替尼联合化疗用于一线及以上化疗失败后晚期胃癌的临床疗效[J].中国肿瘤生物治疗杂志，2018，25（11）：1135-1139.
[4]	刘桢，邓立春，曹向明，等.阿帕替尼联合替吉奥二线治疗晚期胃癌的疗效及安全性观察[J].医药前沿，2020，10（27）：48-50.
[5]	林晓伟，林尤恩，王晓芬.多西他赛联合阿帕替尼二线治疗晚期胃癌的临床效果[J].中国当代医药，2020，27（17）：85-88，92.
[6]	宋滨，隋超.阿帕替尼联合化疗对晚期胃癌化疗后进展的疗效及安全性观察[J].中国实用医药，2020，15（31）：102-104.
[7]	赵鑫.阿帕替尼联合紫杉醇治疗晚期化疗耐药HER-2 阴性胃癌的临床效果评价[J].中外医疗，2017，36（35）：127-129.
[8]	毕志彬，胡文庆，张康康，等.阿帕替尼对晚期胃癌的治疗效果.中国实用医刊，2019，46（19）：96-98.
[9]	潘妍，施育鹏.阿帕替尼联合化疗对于晚期胃癌患者生存周期及血清sIL-2R,VEGF 水平的影响[J].中国中西医结合消化杂志，2019，27（2）：111-115.
[10]	赵丹，朱剑梅，杨林.甲胎蛋白阳性与阳性胃癌患者采用阿帕替尼联合二线化疗方案治疗的临床效果比较[J].医药前沿，2019，9（26）：112-113.
[14]	冯艳飞.阿帕替尼联合化疗治疗晚期胃癌的临床疗效和安全性分析[J].中国疗养医学，2020，29（3）：324-326.
[15]	李琳，蔡晓军.阿帕替尼联合紫杉醇二线治疗晚期食管癌的临床研究[J].实用肿瘤杂志，2020，35（3）：55-58.
[16]	张晖，高立伟，闫江涛，等.紫杉醇单药及与小剂量阿帕替尼联合治疗一线化疗失败晚期胃癌的近期疗效比较[J].中国实用医刊，2021，48（8）：88-90.